Lu-TARGO (177Lu-TARGeted Osteosarcoma Therapy)
A phase 1/2 trial of LNTH2403 Phase 1 dose in osteosarcoma, run by Lantheus Medical Imaging, now recruiting.
Overview
Lu-TARGO (177Lu-TARGeted Osteosarcoma Therapy) is a phase 1/2 interventional study registered as NCT07357519 by Lantheus Medical Imaging, with 55 participants planned, started 2026-02-03 and due to reach its primary completion in 2027-08. Interventions recorded: LNTH2403 Phase 1 dose and Phase 2; LNTH2403 a single agent recommended phase 2 dose (RP2D)..
Similar pages
not linked directly; found by shared links- Trial64Cu-LNTH-1363S in Patients With Sarcoma or Gastrointestinal Tract Cancer
Shares Lantheus and the tag pipeline.
- TrialPhase 1/2 Clinical Study of Lutetium Lu 177 JH020002 Injection in Patients With Advanced Prostate Cancer
Shares Lutetium-177 and the tag pipeline.
- TrialAn Open-label Phase 3 Study of Lutetium (177Lu) Oxodotreotide Injection in Subjects With Advanced Gastrointestinal Pancreatic Neuroendocrine Tumors.
Shares Lutetium-177 and the tag pipeline.
- TrialA Dose Escalation and Expansion Study of [177Lu]Lu-SN201 in Participants With Advanced Cancer
Shares Lutetium-177 and the tag pipeline.
- TrialStudy to Evaluate the Efficacy and Safety of [177Lu]Lu-DOTA-TATE in Patients With Grade 1 and Grade 2 Advanced GEP-NET
Shares Lutetium-177 and the tag pipeline.
- TrialA Study to Assess Safety, Tolerability and Imaging Characteristics of [68Ga]Ga-DPI-4452 and to Assess Safety, Tolerability, and Efficacy of [177Lu]Lu-DPI-4452 in Participants With Unresectable Locally Advanced or Metastatic Solid Tumors
Shares Lutetium-177 and the tag pipeline.
- TrialA Phase 1/2 Study of 177Lu-NYM032 Injection in mCRPC
Shares Lutetium-177 and the tag pipeline.
- Trial177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors
Shares Lutetium-177 and the tag pipeline.